|
1
|
Ayala-Dominguez L, Olmedo-Nieva L,
Munoz-Bello JO, Contreras-Paredes A, Manzo-Merino J,
Martinez-Ramirez I and Lizano M: Mechanisms of vasculogenic mimicry
in ovarian cancer. Front Oncol. 9:9982019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu Y, Li Q, Li XY, Yang QY, Xu WW and Liu
GL: Short-term anti-vascular endothelial growth factor treatment
elicits vasculogenic mimicry formation of tumors to accelerate
metastasis. J Exp Clin Cancer Res. 31:162012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yin M, Li C, Li X, Lou G, Miao B, Liu X,
Meng F, Zhang H, Chen X, Sun M, et al: Over-expression of LAPTM4B
is associated with poor prognosis and chemotherapy resistance in
stages III and IV epithelial ovarian cancer. J Surg Oncol.
104:29–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Williams TI, Toups KL, Saggese DA, Kalli
KR, Cliby WA and Muddiman DC: Epithelial ovarian cancer: Disease
etiology, treatment, detection, and investigational gene,
metabolite, and protein biomarkers. J Proteome Res. 6:2936–2962.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lino-Silva LS: Ovarian carcinoma:
Pathology review with an emphasis in their molecular
characteristics. Chin Clin Oncol. 9:452020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McCluggage WG, Judge MJ, Clarke BA,
Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X,
Mikami Y, Stewart CJ, et al: Data set for reporting of ovary,
fallopian tube and primary peritoneal carcinoma: Recommendations
from the international collaboration on cancer reporting (ICCR).
Mod Pathol. 28:1101–1122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Momenimovahed Z, Tiznobaik A, Taheri S and
Salehiniya H: Ovarian cancer in the world: Epidemiology and risk
factors. Int J Womens Health. 11:287–299. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El-Sherif A, El-Sherif S, Taylor AH and
Ayakannu T: Ovarian cancer: Lifestyle, diet and nutrition. Nutr
Cancer. 73:1092–1107. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fan YZ and Sun M: Molecular regulation of
vasculogenic mimicry in tumors and potential tumor-target therapy.
World J Gastrointest Surg. 2:117–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang X, Su P, Hao Q, Zhang X, Xia L and
Zhang Y: A Chinese classical prescription Guizhi-Fuling Wan in
treatment of ovarian cancer: An overview. Biomed Pharmacother.
153:1134012022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chavoshi H, Poormolaie N, Vahedian V,
Kazemzadeh H, Mir A, Nejabati HR, Behroozi J, Isazadeh A,
Hajezimian S, Nouri M and Maroufi NF: Vascular mimicry: A potential
therapeutic target in breast cancer. Pathol Res Pract.
234:1539222022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marques dos Reis E and Berti FV:
Vasculogenic mimicry-an overview. Methods Mol Biol. 2514:3–13.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Salinas-Vera YM, Gallardo-Rincón D,
Ruíz-García E, Marchat LA, Valdés J, Vázquez-Calzada C and
López-Camarillo C: A three-dimensional culture-based assay to
detect early stages of vasculogenic mimicry in ovarian cancer
cells. Methods Mol Biol. 2514:53–60. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Folberg R and Maniotis AJ: Vasculogenic
mimicry. APMIS. 112:508–525. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang SY, Ke YQ, Lu GH, Song ZH, Yu L, Xiao
S, Sun XL, Jiang XD, Yang ZL and Hu CC: Vasculogenic mimicry is a
prognostic factor for postoperative survival in patients with
glioblastoma. J Neurooncol. 112:339–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen L, Lin ZX, Lin GS, Zhou CF, Chen YP,
Wang XF and Zheng ZQ: Classification of microvascular patterns via
cluster analysis reveals their prognostic significance in
glioblastoma. Hum Pathol. 46:120–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Quaresmini D and Guida M: Neoangiogenesis
in melanoma: An issue in biology and systemic treatment. Front
Immunol. 11:5849032020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pastorino O, Gentile MT, Mancini A, Del
Gaudio N, Di Costanzo A, Bajetto A, Franco P, Altucci L, Florio T,
Stoppelli MP and Colucci-D'Amato L: Histone deacetylase inhibitors
impair vasculogenic mimicry from glioblastoma cells. Cancers
(Basel). 11:7472019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng N, Zhang S, Wu W, Zhang N and Wang
J: Regulatory mechanisms and therapeutic targeting of vasculogenic
mimicry in hepatocellular carcinoma. Pharmacol Res. 166:1055072021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Shi F, Tao R, Wu J, Gu J, Yang R
and Wu S: The relationship Between UBE2C and AGGF1 overexpression
and tumor angiogenesis in non-small cell lung cancer. Cancer Manag
Res. 13:5919–5930. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi L, Song W, Liu Z, Zhao X, Cao W and Sun
B: Wnt3a promotes the vasculogenic mimicry formation of colon
cancer via Wnt/β-catenin signaling. Int J Mol Sci. 16:18564–18579.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo Y, Yang Z, Yu Y and Zhang P: HIF1α
lactylation enhances KIAA1199 transcription to promote angiogenesis
and vasculogenic mimicry in prostate cancer. Int J Biol Macromol.
222:2225–2243. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Salem A and Salo T: Vasculogenic mimicry
in head and neck squamous cell carcinoma-time to take notice. Front
Oral Health. 2:6668952021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
You B, Sun Y, Luo J, Wang K, Liu Q, Fang
R, Liu B, Chou F, Wang R, Meng J, et al: Androgen receptor promotes
renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering
TWIST1 nonsense-mediated decay through lncRNA-TANAR. Oncogene.
40:1674–1689. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Seftor RE, Hess AR, Seftor EA, Kirschmann
DA, Hardy KM, Margaryan NV and Hendrix MJ: Tumor cell vasculogenic
mimicry: From controversy to therapeutic promise. Am J Pathol.
181:1115–1125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Andreucci E, Peppicelli S, Ruzzolini J,
Bianchini F, Biagioni A, Papucci L, Magnelli L, Mazzanti B, Stecca
B and Calorini L: The acidic tumor microenvironment drives a
stem-like phenotype in melanoma cells. J Mol Med (Berl).
98:1431–1446. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu H, Ma T, Liu N, Hong H, Yu L, Lyu D,
Meng X, Wang B and Jiang X: Immunotherapy checkpoints in ovarian
cancer vasculogenic mimicry: Tumor immune microenvironments, and
drugs. Int Immunopharmacol. 111:1091162022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Annett S, Moore G, Short A, Marshall A,
McCrudden C, Yakkundi A, Das S, McCluggage WG, Nelson L, Harley I,
et al: FKBPL-based peptide, ALM201, targets angiogenesis and cancer
stem cells in ovarian cancer. Br J Cancer. 122:361–371. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Graupera M and Potente M: Regulation of
angiogenesis by PI3K signaling networks. Exp Cell Res.
319:1348–1355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morales-Guadarrama G, García-Becerra R,
Méndez-Pérez EA, García-Quiroz J, Avila E and Díaz L: Vasculogenic
mimicry in breast cancer: Clinical relevance and drivers. Cells.
10:17582021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Giannotta M, Trani M and Dejana E:
VE-cadherin and endothelial adherens junctions: Active guardians of
vascular integrity. Dev Cell. 26:441–454. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Giannelli G, Falk-Marzillier J, Schiraldi
O, Stetler-Stevenson WG and Quaranta V: Induction of cell migration
by matrix metalloprotease-2 cleavage of laminin-5. Science.
277:225–258. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koshikawa N, Giannelli G, Cirulli V,
Miyazaki K and Quaranta V: Role of cell surface metalloprotease
MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol.
148:615–624. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang J, Wang J, Fan L, Li X, Liu N, Luo W,
Wang J and Wang Y and Wang Y: cRGD inhibits vasculogenic mimicry
formation by down-regulating uPA expression and reducing EMT in
ovarian cancer. Oncotarget. 7:24050–24062. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ediriweera MK, Tennekoon KH and Samarakoon
SR: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer:
Biological and therapeutic significance. Semin Cancer Biol.
59:147–160. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qi H, Sun B, Zhao X, Du J, Gu Q, Liu Y,
Cheng R and Dong X: Wnt5a promotes vasculogenic mimicry and
epithelial-mesenchymal transition via protein kinase Cα in
epithelial ovarian cancer. Oncol Rep. 32:771–779. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bapat SA, Mali AM, Koppikar CB and Kurrey
NK: Stem and progenitor-like cells contribute to the aggressive
behavior of human epithelial ovarian cancer. Cancer Res.
65:3025–3029. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Taniguchi H, Suzuki Y and Natori Y: The
evolving landscape of cancer stem cells and ways to overcome cancer
heterogeneity. Cancers (Basel). 11:5322019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang HF, Wang SS, Zheng M, Dai LL, Wang K,
Gao XL, Cao MX, Yu XH, Pang X, Zhang M, et al: Hypoxia promotes
vasculogenic mimicry formation by vascular endothelial growth
factor A mediating epithelial-mesenchymal transition in salivary
adenoid cystic carcinoma. Cell Prolif. 52:e126002019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gest C, Mirshahi P, Li H, Pritchard LL,
Joimel U, Blot E, Chidiac J, Poletto B, Vannier JP, Varin R, et al:
Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets.
Cancer Lett. 317:207–217. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dongre A and Weinberg RA: New insights
into the mechanisms of epithelial-mesenchymal transition and
implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sicard AA, Dao T, Suarez NG and Annabi B:
Diet-derived gallated catechins prevent TGF-β-mediated
epithelial-mesenchymal transition, cell migration and vasculogenic
mimicry in chemosensitive ES-2 ovarian cancer cells. Nutr Cancer.
73:169–180. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sun B, Zhang D, Zhao N and Zhao X:
Epithelial-to-endothelial transition and cancer stem cells: Two
cornerstones of vasculogenic mimicry in malignant tumors.
Oncotarget. 8:30502–30510. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao X, Sun B, Li Y, Liu Y, Zhang D, Wang
X, Gu Q, Zhao J, Dong X, Liu Z and Che N: Dual effects of
collagenase-3 on melanoma: Metastasis promotion and disruption of
vasculogenic mimicry. Oncotarget. 6:8890–8899. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Su M, Wei W, Xu X, Wang X, Chen C, Su L
and Zhang Y: Role of hCG in vasculogenic mimicry in OVCAR-3 ovarian
cancer cell line. Int J Gynecol Cancer. 21:1366–1374. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gao S, Fan C, Huang H, Zhu C, Su M and
Zhang Y: Effects of HCG on human epithelial ovarian cancer
vasculogenic mimicry formation in vivo. Oncol Lett.
12:459–466. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang Y, Liu P, Wang X and Mao H: Role of
X-linked inhibitor of apoptosis-associated factor-1 in vasculogenic
mimicry in ovarian cancer. Mol Med Rep. 16:325–330. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ashburn TT and Thor KB: Drug
repositioning: Identifying and developing new uses for existing
drugs. Nat Rev Drug Discov. 3:673–683. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang S, Long S, Deng Z and Wu W: Positive
role of Chinese herbal medicine in cancer immune regulation. Am J
Chin Med. 48:1577–1592. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hernández de la Cruz ON, López-González
JS, García-Vázquez R, Salinas-Vera YM, Muñiz-Lino MA,
Aguilar-Cazares D, López-Camarillo C and Carlos-Reyes Á: Regulation
networks driving vasculogenic mimicry in solid tumors. Front Oncol.
9:14192019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mahfouz N, Tahtouh R, Alaaeddine N, El
Hajj J, Sarkis R, Hachem R, Raad I and Hilal G: Gastrointestinal
cancer cells treatment with bevacizumab activates a VEGF
autoregulatory mechanism involving telomerase catalytic subunit
hTERT via PI3K-AKT, HIF-1α and VEGF receptors. PLoS One.
12:e01792022017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu H and Huang J: Optimization of protein
and peptide drugs based on the mechanisms of kidney clearance.
Protein Pept Lett. 25:514–521. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pinto MP, Sotomayor P, Carrasco-Avino G,
Corvalan AH and Owen GI: Escaping antiangiogenic therapy:
Strategies employed by cancer cells. Int J Mol Sci. 17:14892016.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Vasudev NS and Reynolds AR:
Anti-angiogenic therapy for cancer: Current progress, unresolved
questions and future directions. Angiogenesis. 17:471–494. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lu XS, Sun W, Ge CY, Zhang WZ and Fan YZ:
Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin
signaling pathways to tumor growth and vasculogenic mimicry of
gallbladder carcinomas. Int J Oncol. 42:2103–2115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Altinoz MA, Topcu G, Hacimuftuoglu A,
Ozpinar A, Ozpinar A, Hacker E and Elmaci I: Noscapine, a
non-addictive opioid and microtubule-inhibitor in potential
treatment of glioblastoma. Neurochem Res. 44:1796–1806. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Su W, Huang L, Ao Q, Zhang Q, Tian X, Fang
Y and Lu Y: Noscapine sensitizes chemoresistant ovarian cancer
cells to cisplatin through inhibition of HIF-1α. Cancer Lett.
305:94–99. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Peach ML, Beedie SL, Chau CH, Collins MK,
Markolovic S, Luo W, Tweedie D, Steinebach C, Greig NH, Gütschow M,
et al: Antiangiogenic activity and in silico cereblon binding
analysis of novel thalidomide analogs. Molecules. 25:56832020.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang S, Li M, Gu Y, Liu Z, Xu S, Cui Y
and Sun B: Thalidomide influences growth and vasculogenic mimicry
channel formation in melanoma. J Exp Clin Cancer Res. 27:602008.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nozawa-Suzuki N, Nagasawa H, Ohnishi K and
Morishige K: The inhibitory effect of hypoxic cytotoxin on the
expansion of cancer stem cells in ovarian cancer. Biochem Biophys
Res Commun. 457:706–711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liu K, Zhang X, Xie L, Deng M, Chen H,
Song J, Long J, Li X and Luo J: Lupeol and its derivatives as
anticancer and anti-inflammatory agents: Molecular mechanisms and
therapeutic efficacy. Pharmacol Res. 164:1053732021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bhattacharyya S, Mitra D, Ray S, Biswas N,
Banerjee S, Majumder B, Mustafi SM and Murmu N: Reversing effect of
Lupeol on vasculogenic mimicry in murine melanoma progression.
Microvasc Res. 121:52–62. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bae H, Lee JY, Yang C, Song G and Lim W:
Fucoidan derived from fucus vesiculosus inhibits the development of
human ovarian cancer via the disturbance of calcium homeostasis,
endoplasmic reticulum stress, and angiogenesis. Mar Drugs.
18:452020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sicard AA, Dao T, Suarez NG and Annabi B:
Diet-derived gallated catechins prevent TGF-beta-mediated
epithelial-mesenchymal transition, cell migration and vasculogenic
mimicry in chemosensitive ES-2 ovarian cancer cells. Nutr Cancer.
73:169–180. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Shi X, Chen Z, Wang Y, Guo Z and Wang X:
Hypotoxic copper complexes with potent anti-metastatic and
anti-angiogenic activities against cancer cells. Dalton Trans.
47:5049–5054. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Liu T, Zhao L, Zhang Y, Chen W, Liu D, Hou
H, Ding L and Li X: Ginsenoside 20(S)-Rg3 targets HIF-1alpha to
block hypoxia-induced epithelial-mesenchymal transition in ovarian
cancer cells. PLoS One. 9:e1038872014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Xu MR, Wei PF, Suo MZ, Hu Y, Ding W, Su L,
Zhu YD, Song WJ, Tang GH, Zhang M and Li P: Brucine suppresses
vasculogenic mimicry in human triple-negative breast cancer cell
line MDA-MB-231. Biomed Res Int. 2019:65432302019.PubMed/NCBI
|
|
70
|
Xiao T, Zhong W, Zhao J, Qian B, Liu H,
Chen S, Qiao K, Lei Y, Zong S, Wang H, et al: Polyphyllin I
suppresses the formation of vasculogenic mimicry via
Twist1/VE-cadherin pathway. Cell Death Dis. 9:9062018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Phillips TM and Lindsey JS: Carcinoma
cell-specific Mig-7: A new potential marker for circulating and
migrating cancer cells. Oncol Rep. 13:37–44. 2005.PubMed/NCBI
|
|
72
|
Crouch S, Spidel CS and Lindsey JS: HGF
and ligation of alphavbeta5 integrin induce a novel, cancer
cell-specific gene expression required for cell scattering. Exp
Cell Res. 292:274–287. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Huang B, Yin M, Li X, Cao G, Qi J, Lou G,
Sheng S, Kou J, Chen K and Yu B: Migration-inducing gene 7 promotes
tumorigenesis and angiogenesis and independently predicts poor
prognosis of epithelial ovarian cancer. Oncotarget. 7:27552–27566.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Sun Q, Zou X, Zhang T, Shen J, Yin Y and
Xiang J: The role of miR-200a in vasculogenic mimicry and its
clinical significance in ovarian cancer. Gynecol Oncol.
132:730–738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Liu W, Lv C, Zhang B, Zhou Q and Cao Z:
MicroRNA-27b functions as a new inhibitor of ovarian
cancer-mediated vasculogenic mimicry through suppression of
VE-cadherin expression. RNA. 23:1019–1027. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kristensen LS, Andersen MS, Stagsted LVW,
Ebbesen KK, Hansen TB and Kjems J: The biogenesis, biology and
characterization of circular RNAs. Nat Rev Genet. 20:675–691. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Guan X, Zong ZH, Liu Y, Chen S, Wang LL
and Zhao Y: circPUM1 promotes tumorigenesis and progression of
ovarian cancer by sponging miR-615-5p and miR-6753-5p. Mol Ther
Nucleic Acids. 18:882–892. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Shao Y and Lu B: The emerging roles of
circular RNAs in vessel co-option and vasculogenic mimicry:
Clinical insights for anti-angiogenic therapy in cancers. Cancer
Metastasis Rev. 41:173–191. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Li J, Ke Y, Huang M, Huang S and Liang Y:
Inhibitory effects of B-cell lymphoma 2 on the vasculogenic mimicry
of hypoxic human glioma cells. Exp Ther Med. 9:977–981. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Li T, Zhang C, Hassan S, Liu X, Song F,
Chen K, Zhang W and Yang J: Histone deacetylase 6 in cancer. J
Hematol Oncol. 11:1112018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Treps L, Faure S and Clere N: Vasculogenic
mimicry, a complex and devious process favoring
tumorigenesis-interest in making it a therapeutic target. Pharmacol
Ther. 223:1078052021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ledermann JA, Embleton AC, Raja F, Perren
TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan
M, et al: Cediranib in patients with relapsed platinum-sensitive
ovarian cancer (ICON6): A randomised, double-blind,
placebo-controlled phase 3 trial. Lancet. 387:1066–1074. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lim D, Do Y, Kwon BS, Chang W, Lee MS, Kim
J and Cho JG: Angiogenesis and vasculogenic mimicry as therapeutic
targets in ovarian cancer. BMB Rep. 53:291–298. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sun H, Zhang D, Yao Z, Lin X, Liu J, Gu Q,
Dong X, Liu F, Wang Y, Yao N, et al: Anti-angiogenic treatment
promotes triple-negative breast cancer invasion via vasculogenic
mimicry. Cancer Biol Ther. 18:205–213. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Sun M, Li H, Liu J, Ning L, Zhao D and Liu
S: The relationship between TEM8 and early diagnosis and prognosis
of lung cancer. Minerva Med. 112:359–364. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zhang C, Chen W, Zhang X, Huang B, Chen A,
He Y, Wang J and Li X: Galunisertib inhibits glioma vasculogenic
mimicry formation induced by astrocytes. Sci Rep. 6:230562016.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang Y, Xu Y, Ma J, Pang X and Dong M:
Adrenomedullin promotes angiogenesis in epithelial ovarian cancer
through upregulating hypoxia-inducible factor-1α and vascular
endothelial growth factor. Sci Rep. 7:405242017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Guo T, Yu W, Lv S, Zhang C and Tian Y:
MiR-302a inhibits the tumorigenicity of ovarian cancer cells by
suppression of SDC1. Int J Clin Exp Pathol. 8:4869–4880.
2015.PubMed/NCBI
|
|
89
|
Wang Y, Tong L, Wang J, Luo J, Tang J,
Zhong L, Xiao Q, Niu W, Li J, Zhu J, et al: cRGD-functionalized
nanoparticles for combination therapy of anti-endothelium dependent
vessels and anti-vasculogenic mimicry to inhibit the proliferation
of ovarian cancer. Acta Biomater. 94:495–504. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Dueñas-Garcia OF, Diaz-Sotomayor M and
Rico-Olvera H: Utility of the pulsatility index of the uterine
arteries and human chorionic gonadotropin in a series of cases of
placenta accreta. J Obstet Gynaecol Res. 37:1112–1116. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Jiang J, Chen Y, Zhang M, Zhou H and Wu H:
Relationship between CD177 and the vasculogenic mimicry,
clinicopathological parameters, and prognosis of epithelial ovarian
cancer. Ann Palliat Med. 9:3985–3992. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Liang J, Yang B, Cao Q and Wu X:
Association of vasculogenic mimicry formation and CD133 expression
with poor prognosis in ovarian cancer. Gynecol Obstet Invest.
81:529–536. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Yu L, Zhu B, Wu S, Zhou L, Song W, Gong X
and Wang D: Evaluation of the correlation of vasculogenic mimicry,
ALDH1, KiSS-1, and MACC1 in the prediction of metastasis and
prognosis in ovarian carcinoma. Diagn Pathol. 12:232017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Recouvreux MS, Miao J, Gozo MC, Wu J,
Walts AE, Karlan BY and Orsulic S: FOXC2 promotes vasculogenic
mimicry in ovarian cancer. Cancers (Basel). 14:48512022. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ocaña OH, Córcoles R, Fabra A,
Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A and
Nieto MA: Metastatic colonization requires the repression of the
epithelial-mesenchymal transition inducer Prrx1. Cancer Cell.
22:709–724. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Ding J, Jia X, Zuo B, He J, Yang J and He
Y: A novel monoclonal antibody targeting a novel epitope of
VE-cadherin inhibits vasculogenic mimicry of lung cancer cells.
Oncol Rep. 39:2837–2844. 2018.PubMed/NCBI
|
|
97
|
Liu LZ, Jing Y, Jiang LL, Jiang XE, Jiang
Y, Rojanasakul Y and Jiang BH: Acacetin inhibits VEGF expression,
tumor angiogenesis and growth through AKT/HIF-1α pathway. Biochem
Biophys Res Commun. 413:299–305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Morales-Guadarrama G, Mendez-Perez EA,
Garcia-Quiroz J, Avila E, Garcia-Becerra R, Zentella-Dehesa A,
Larrea F and Díaz L: Endothelium-dependent induction of
vasculogenic mimicry in human triple-negative breast cancer cells
is inhibited by calcitriol and curcumin. Int J Mol Sci.
23:76592022. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Selick HE, Beresford AP and Tarbit MH: The
emerging importance of predictive ADME simulation in drug
discovery. Drug Discov Today. 7:109–116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Tang HS, Feng YJ and Yao LQ: Angiogenesis,
vasculogenesis, and vasculogenic mimicry in ovarian cancer. Int J
Gynecol Cancer. 19:605–610. 2009. View Article : Google Scholar : PubMed/NCBI
|
